Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/BridgeBio submits FDA NDA for encaleret, a potential first therapy for ADH1, with Phase 3 success.
BBIO
$82.33
-$0.33 -0.41%

BridgeBio submits FDA NDA for encaleret, a potential first therapy for ADH1, with Phase 3 success.

Market News
12 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret, targeting autosomal dominant hypocalcemia type 1 (ADH1). The Phase 3 CALIBRATE trial showed encaleret met all primary and key secondary endpoints, normalizing calcium levels in 76% of patients versus 4% on standard therapy. The drug demonstrated rapid, sustained benefits and a favorable safety profile, potentially becoming the first approved treatment for ADH1. BridgeBio plans a U.S. launch in early 2027 and will also seek approval in Europe while expanding trials to pediatric and chronic hypoparathyroidism populations.

More News (BBIO)

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma stays a strong buy with key drug approvals and $1B funding boost.

BridgeBio Pharma remains a strong buy due to regulatory approvals for its drug acoramidis and positive clinical data for infigratinib in achondroplasia. The company expects $180.6 million in U.S. net product revenue by Q1 2026 and targets a $2.9 bill...

Analyst Insights
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App